Zacks Research Equities Analysts Cut Earnings Estimates for IQVIA Holdings Inc. (NYSE:IQV)

IQVIA Holdings Inc. (NYSE:IQVFree Report) – Analysts at Zacks Research reduced their Q2 2024 EPS estimates for IQVIA in a note issued to investors on Thursday, May 23rd. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $2.39 per share for the quarter, down from their previous estimate of $2.46. The consensus estimate for IQVIA’s current full-year earnings is $10.11 per share. Zacks Research also issued estimates for IQVIA’s Q3 2024 earnings at $2.52 EPS, Q4 2024 earnings at $2.88 EPS, FY2024 earnings at $10.09 EPS, Q1 2025 earnings at $2.55 EPS, Q2 2025 earnings at $2.71 EPS, Q3 2025 earnings at $2.97 EPS, Q4 2025 earnings at $3.07 EPS, FY2025 earnings at $11.30 EPS, Q1 2026 earnings at $2.92 EPS and FY2026 earnings at $12.70 EPS.

IQVIA (NYSE:IQVGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The business had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion.

Other research analysts have also recently issued research reports about the stock. Barclays raised their target price on shares of IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Evercore ISI reduced their price objective on IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a research note on Friday, May 3rd. SVB Leerink assumed coverage on IQVIA in a report on Monday, February 26th. They issued an “outperform” rating and a $290.00 price objective for the company. UBS Group raised their target price on IQVIA from $240.00 to $300.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Finally, Leerink Partnrs reissued an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $257.57.

View Our Latest Stock Report on IQVIA

IQVIA Stock Performance

IQV opened at $229.60 on Monday. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 2.02. IQVIA has a 12-month low of $167.42 and a 12-month high of $261.73. The firm has a 50 day moving average of $236.65 and a two-hundred day moving average of $229.20. The firm has a market capitalization of $41.83 billion, a PE ratio of 31.37, a P/E/G ratio of 2.09 and a beta of 1.52.

Insiders Place Their Bets

In other news, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the transaction, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ari Bousbib sold 31,678 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Private Advisor Group LLC grew its holdings in IQVIA by 1.2% in the 3rd quarter. Private Advisor Group LLC now owns 4,818 shares of the medical research company’s stock valued at $948,000 after buying an additional 56 shares in the last quarter. NBC Securities Inc. acquired a new stake in IQVIA during the third quarter worth about $541,000. Victory Capital Management Inc. increased its position in IQVIA by 3.4% during the third quarter. Victory Capital Management Inc. now owns 105,163 shares of the medical research company’s stock worth $20,691,000 after purchasing an additional 3,413 shares during the last quarter. Versor Investments LP purchased a new position in IQVIA during the third quarter worth about $525,000. Finally, Illinois Municipal Retirement Fund boosted its holdings in IQVIA by 26.6% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 12,141 shares of the medical research company’s stock valued at $2,389,000 after purchasing an additional 2,552 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

(Get Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also

Earnings History and Estimates for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.